author-photo

Michael McCleod

Sarah Cannon Research Institute

53

Papers

2321

Citations

Citation Trend

Filter By

Papers (37) Sort By

Journal Conference Others

nab-Paclitaxel Plus Carboplatin Induction Followed by nab-Paclitaxel Maintenance in Squamous Non-Small Cell Lung Cancer (ABOUND.sqm): A Phase 3 Randomized Clinical Trial

2020 Clinical Lung Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (30)
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

2019 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (438)
Safety, Efficacy, and Patient-reported Health-related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged ≥70 Years or with Poor Performance Status (CheckMate 153)

2019 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (77)
A Randomized, Double‐Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX‐427) in Patients with Previously Untreated Stage IV Non‐Squamous‐Non‐Small‐Cell Lung Cancer: The SPRUCE Trial

2019 Oncologist
Show All
- Source
- Cite
- Save
Citations (15)
LBA64nab-paclitaxel + carboplatin induction followed by nab-paclitaxel maintenance in squamous non-small cell lung cancer (NSCLC): Results from the ABOUND.sqm study

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
LBA53IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (40)
Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153

2018 Cancer Chemotherapy and Pharmacology
Show All
- Source
- Cite
- Save
Citations (6)
Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study

2017 Investigational New Drugs
Show All
- Source
- Cite
- Save
Citations (20)
P3.02c-026 Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153: Topic: IT

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (37)